Beyond darunavir: recent development of next generation HIV-1 protease inhibitors to combat drug resistance. Issue 84 (6th October 2022)

• Record Type: Journal Article
• Authors: Ghosh, Arun K.; Weber, Irene T.; Mitsuya, Hiroaki
• Is Part Of: Chemical communications. Volume 58:Issue 84(2022)
• Page Start: 11762
• Page End: 11782
• Publication Date: 2022-10-06
• Subjects: Chemistry -- Periodicals; 540
• DOI: 10.1039/d2cc04541a
• Languages: English
• ISSNs: 1359-7345

Abstract

Abstract : We describe design and syntheses of a new generation of exceptionally highly potent non-peptidic HIV-1 protease inhibitors. Abstract : We report our recent development of a conceptually new generation of exceptionally potent non-peptidic HIV-1 protease inhibitors that displayed excellent pharmacological and drug-resistance profiles. Our X-ray structural studies of darunavir and other designed inhibitors from our laboratories led us to create a variety of inhibitors incorporating fused ring polycyclic ethers and aromatic heterocycles to promote hydrogen bonding interactions with the backbone atoms of HIV-1 protease as well as van der Waals interactions with residues in the S2 and S2′ subsites. We have also incorporated specific functionalities to enhance van der Waals interactions in the S1 and S1′ subsites. The combined effects of these structural templates are critical to the inhibitors' exceptional potency and drug-like properties. We highlight here our molecular design strategies to promote backbone hydrogen bonding interactions to combat drug-resistance and specific design of polycyclic ether templates to mimic peptide-like bonds in the HIV-1 protease active site. Our medicinal chemistry and drug development efforts led to the development of new generation inhibitors significantly improved over darunavir and displaying unprecedented antiviral activity against multidrug-resistant HIV-1 variants.